Key facts
- Episteme Prognostics’s last known valuation is $10.0M (Apr 2023).
- It has raised $6.6M across 2 recorded rounds; the latest was Seed Round ($550K) in Feb 2025.
- Notable investors include DRIVEN Accelerator Hub.
- Episteme Prognostics has filed 4 Form Ds with the SEC since 2022, most recently Mar 2025 ($550K sold to 1 investors).
- Status: Privately Held (backing).
Investors
1Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Episteme Prognostics
Create free account
No card required
Funding rounds
2 roundsAbout Episteme Prognostics
Operator of a precision medicine company intended to improve the treatment of pancreatic cancer. The company is currently operating in Stealth Mode.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2021
- Employees
- 2
- Website
- epistemedx.com/
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
Episteme Prognostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Episteme Prognostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Episteme Prognostics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.